The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye

Gül, Fethi; Kasapoğlu, Umut Sabri; Sabaz, Mehmet Süleyman; Ay, Pınar; Oktay, Burçin Doruk; Çalışkan, Gülbahar; Demir, Nalan; Alparslan, Mustafa Muhlis

The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye

dc.contributor.author	Gül, Fethi
dc.contributor.author	Kasapoğlu, Umut Sabri
dc.contributor.author	Sabaz, Mehmet Süleyman
dc.contributor.author	Ay, Pınar
dc.contributor.author	Oktay, Burçin Doruk
dc.contributor.author	Çalışkan, Gülbahar
dc.contributor.author	Demir, Nalan
dc.contributor.author	Alparslan, Mustafa Muhlis
dc.date.accessioned	2024-04-19T13:43:21Z
dc.date.available	2024-04-19T13:43:21Z
dc.date.issued	2023
dc.department	Tıp Fakültesi
dc.description.abstract	Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear. Aims: To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19. Study Design: Multicenter prospective observational clinical study. Methods: This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19. Patients aged ? 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated. Results: As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 ± 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (p < 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (p = 0.004). Conclusion: Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients.
dc.identifier.doi	10.4274/balkanmedj.galenos.2023.2023-6-90
dc.identifier.endpage	440	en_US
dc.identifier.issn	2146-3123
dc.identifier.issue	6	en_US
dc.identifier.pmid	37867428
dc.identifier.scopusquality	Q1
dc.identifier.startpage	435	en_US
dc.identifier.uri	https:/dx.doi.org10.4274/balkanmedj.galenos.2023.2023-6-90
dc.identifier.uri	https://hdl.handle.net/20.500.12451/11669
dc.identifier.volume	40	en_US
dc.identifier.wos	WOS:001094980300009
dc.identifier.wosquality	Q2
dc.indekslendigikaynak	Web of Science
dc.indekslendigikaynak	Scopus
dc.indekslendigikaynak	PubMed
dc.language.iso	en
dc.publisher	Galenos Publishing House
dc.relation.ispartof	Balkan Medical Journal
dc.relation.publicationcategory	Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rights	Attribution-NonCommercial-NoDerivs 3.0 United States	*
dc.rights	info:eu-repo/semantics/openAccess
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.subject	Aged
dc.subject	Aged
dc.subject	80 and over
dc.title	The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye
dc.type	Article